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Summary
In 2014, there were 36.9 million people worldwide living
with human immunodeficiency virus (PLWH), of whom
17.1 million did not know they were infected. Whilst the
number of new human immunodeficiency virus (HIV) in-
fections has declined globally since 2000, there are still re-
gions where new infection rates are rising, and diagnosing
HIV early in the course of infection remains a challenge.
Late presentation to care in HIV refers to individuals newly
presenting for HIV care with a CD4 count below 350 cells/
µl or with an acquired immune deficiency syndrome
(AIDS)-defining event. Late presentation is associated with
increased patient morbidity and mortality, healthcare costs
and risk of onward transmission by individuals unaware of
their status. Further, late presentation limits the effective-
ness of all subsequent steps in the cascade of HIV care.
Recent figures from 34 countries in Europe show that late
presentation occurs in 38.3% to 49.8% of patients newly
presenting for care, depending on region. In Switzerland,
data from patients enrolled in the Swiss HIV Cohort Study
put the rate of late presentation at 49.8% and show that pa-
tients outside established HIV risk groups are most likely to
be late presenters. Provider-initiated testing needs to be im-
proved to reach these groups, which include heterosexual
men and women and older patients. The aim of this review
is to describe the scale and implications of late presenta-
tion using cohort data from Switzerland and elsewhere in
Europe, and to highlight initiatives to improve early HIV
diagnosis. The importance of recognising indicator condi-
tions and the potential for missed opportunities for HIV
testing is illustrated in three clinical case studies.
Key words: HIV testing; late presentation; missed
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Introduction
One of the United Nations Sustainable Development Goals
for health is to end the HIV epidemic by 2030 [1]. To
achieve this, the Joint United Nations Programme on HIV/
AIDS (UNAIDS) set out the target that 90% of all people
living with HIV will know their HIV status, 90% of all
people with diagnosed HIV infection will receive sustained
antiretroviral therapy (ART) and 90% of all people receiv-
ing ART will have HIV viral suppression by 2020 [1]: in
other words, 90% diagnosed, 90% treated and 90% sup-
pressed. So far, Switzerland is close to reaching this tar-
get: of 15 200 people estimated to be living with HIV in
Switzerland in 2012, 12 300 (81%) were diagnosed, 10 800
(88% of those diagnosed) were receiving ART and 10 400
(96% of those receiving ART) were reported to have sup-
pressed HIV RNA [2, 3]. Although diagnosing HIV infec-
tion is important as the first step in the 90-90-90 target, dia-
gnosis per se is no longer enough. We now have evidence
that early diagnosis optimises patient outcome, and that pa-
tients benefit from ART even at higher CD4 counts (>350
cells/µl) [4, 5]. Conversely, failure to diagnose HIV early is
associated, on a patient level, with increased morbidity and
mortality [6] and, on a public level, with increased health-
care costs [7, 8] and risk of onward transmission [9]. Of
new HIV diagnoses made in the past decade in Switzer-
land, 49.8% were in individuals already at the stage of late
presentation [10].
Over the last three decades, the epidemiology of HIV in-
fection in industrialised countries has changed. In the pre-
ART era, new HIV infections were most frequently in three
classical risk groups: men who have sex with men (MSM),
people who inject drugs (PWID) and individuals with sexu-
al partners from regions of high HIV prevalence, notably
sub-Saharan Africa. The current epidemic is driven by
MSM and heterosexual transmission. Among 519 new HIV
infections reported in 2014 in Switzerland, these groups
accounted for 57% and 42% of cases, respectively, while
PWID accounted for 2% (rounded figures) [11]. Individu-
als not from classical risk groups account for fewer new
HIV infections overall but may be at greater risk of present-
ing late because they are not offered HIV testing by health-
care providers or because they do not consider themselves
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at risk. In order to facilitate early HIV diagnosis, a number
of indicator diseases have been identified. These are con-
ditions either caused by infections which share routes of
transmission with HIV or favoured by immune deficiency,
in which HIV prevalence is sufficiently high to make test-
ing cost-effective [12, 13]. In addition, certain serious non-
AIDS (SNA) conditions, such as cardiovascular, renal and
liver disease, and non-AIDS-defining malignancy, have
been observed to occur more frequently in PLWH than in
HIV-negative individuals [14]. As individuals with HIV
and an SNA event have a risk of death more than six times
greater than that among individuals without an SNA event,
the association between SNA events and HIV is important
to recognise.
This review will focus on late presentation in individuals
who have adequate access to healthcare but who miss being
diagnosed with HIV early in the infection. In this way,
the late presentation epidemiology and risk factors presen-
ted come from Swiss and European cohort data rather than
from those of resource-poor settings. Indicator conditions
and SNA events now included in the Swiss HIV testing
recommendations are presented, together with three case
studies to highlight how linking these to possible HIV in-
fection can avoid missed opportunities for early HIV test-
ing.
Case study 1
A 32-year-old man, previously well, presents to his general
practitioner (GP) complaining of persistent diarrhoea asso-
ciated with weight loss, fatigue and low-grade fever. He is
married with children and has no travel history of note. He
is referred for investigations and seen in two separate hos-
pital gastroenterology departments and a private gastroen-
terology clinic. During the subsequent two years, multiple
diagnostic procedures are performed: two gastroscopies,
three colonoscopies, one capsule endoscopy of the small
bowel, one magnetic resonance imaging (MRI) scan, one
abdominal computed tomography (CT) scan, two abdom-
inal ultrasounds and multiple stool cultures, serology tests
and autoantibody screens. These demonstrate intra-abdom-
inal lymphadenopathy, histiocytic colitis, gastritis and re-
flux oesophagitis; worm-like structures are found on cap-
sule endoscopy but no pathogens are identified on stool
microscopy or culture. In the absence of a conclusive dia-
gnosis, he receives several courses of steroids, mesalazine,
antibiotics and anti-helminth treatments without resolution
of the diarrhoea. Two years after the start of his symptoms,
he self-presents to request anonymous HIV-testing and the
test is positive. On direct questioning, he reports long-
standing regular unprotected sex with men. The CD4 count
is 34 (4%) and HIV RNA viral load is 300 000 copies/ml
at diagnosis. By this time, the patient reports a weight loss
of 25 kg and has cervical lymphadenopathy. Gastrointestin-
al and biliary tract cryptosporidiosis is subsequently identi-
fied.
Methods
We conducted a literature search using PubMed, entering
the following key words separately or in combination:
“late”, “late presenter”, “late presentation”, “missed oppor-
tunities”, “HIV”, “HIV testing”, “Switzerland”, “Europe”.
The case studies presented were selected from those en-
countered at our two centres within the last five years.
Late presentation: definition and
context
According to the European Late Presenter Consensus
Working Group definition published in 2011, late present-
ation for HIV care refers to individuals presenting for care
with a CD4 count below 350 cells/µl, or with an AIDS-de-
fining event regardless of the CD4 cell count [15]. Having
this definition allows comparison of surveillance data and
standardises the way that late presentation risk factors are
identified across different settings. Late presentation fig-
ures in turn are indicators of the success of HIV testing
strategies. Although the updated European AIDS Clinical
Society HIV treatment guidelines now state that ART
should be considered in all patients regardless of CD4
count [4, 5], the limit of 350 cells/µl to define late presenta-
tion remains unchanged at present. Despite some criticisms
of the consensus definition [16], it is the definition used in
this review.
Late presentation can be separated into: late HIV diagnosis,
which reflects the disease stage at the initial positive HIV
test; and delayed presentation for HIV care, which reflects
the time elapsed between initial HIV diagnosis and initial
presentation for HIV medical care [17]. In Europe, less
than 10% of late presentation is believed to result from
delayed presentation for HIV care post-diagnosis [6, 10].
The term “missed opportunities” in the context of late
presentation refers to the situation where an individual has
risk factors for HIV acquisition or presents to a healthcare
provider with symptoms or signs suggestive of HIV infec-
tion, but is not offered a test [18].
Approaches to HIV testing
HIV testing is key in diagnosing HIV early and reducing
late presentation. Three broad approaches to HIV testing
exist: diagnostic testing, performed when a patient presents
with symptoms or signs suggestive of HIV infection; tar-
geted testing, offered to patients with HIV risk factors; and
non-targeted testing, which is a screening approach in pa-
tients who are symptom free. In 2006, the Centers for Con-
trol and Prevention of Diseases recommended non-targeted
HIV testing of all individuals aged 13 to 64 attending a
healthcare system in areas where local HIV seroprevalence
is ≥0.1% [19]. In 2008, the British HIV Association pub-
lished HIV testing guidelines recommending routine (non-
targeted) testing for all individuals at GP registration or
hospital admission in areas where local HIV seroprevalen-
ce is ≥0.2% [20]. In 2011, this recommendation was incor-
porated into the National Institute for Health and Care Ex-
cellence (NICE) guidelines to increase HIV testing among
individuals at higher risk of exposure (in MSM and sub-Sa-
haran African communities) [21, 22].
In Switzerland, where seroprevalence is 0.2 to 0.4% [2,
23], the Federal Office of Public Health (FOPH) published
HIV testing recommendations in 2007 [24], 2010 [25],
2013 [26] and 2015 [27]. These propose Physician-Initiated
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Counselling and Testing (PICT), which is diagnostic, tar-
geted and requires oral patient consent [27]. At Lausanne
University Hospital, no difference in HIV testing rates was
observed in inpatient or outpatient clinical services follow-
ing publication of the 2010 FOPH recommendations [28].
One explanation might have been low awareness of these
recommendations among clinicians. Only 18% of emer-
gency department doctors working in hospitals in French-
speaking Switzerland were aware of the recommendations
[29].
Following the 2010 recommendations, the results of the
HIV Indicator Diseases in Europe Study I (HIDES I), a
European multicentre study of 3588 individuals in 14 coun-
tries across Europe (excluding Switzerland) were published
[13]. HIDES I examined eight indicator diseases to identify
those with HIV prevalence over 0.1%, a threshold shown to
be cost-effective for HIV testing [30, 31]. All eight indicat-
or diseases (shown with an asterisk in table 1) fulfilled the
>0.1% criterion for cost-effectiveness. Importantly, HIV
prevalence exceeded the 0.1% target even among individu-
als presenting with an indicator disease who were not from
high-risk groups. The indicator diseases were added to the
testing indications listed in the updated FOPH testing re-
commendations of 2013 and 2015 [26, 27]. Other condi-
tions, in which not diagnosing HIV would adversely affect
patient management, were also added to these recommend-
ations and are shown in table 2.
Although indicator conditions enable targeted testing be-
fore individuals present with an AIDS-defining event, they
do not facilitate testing among PLWH who are asympto-
matic, who consult healthcare providers for reasons unre-
lated to HIV and who do not disclose risk factors. Taking a
focused sexual history to elicit risk factors depends on the
individual volunteering accurate details. The non-targeted
approach is the only way to test asymptomatic individuals
without discussing risk factors. However, several barriers
to HIV testing exist and relate to policy structure, health-
care providers and patients [32, 33]. Knowledge of the test-
ing barriers specific to each setting enables optimisation of
testing strategies prior to their implementation (De Rossi et
al., unpublished data). Community HIV testing campaigns,
such as offering HIV testing on World AIDS Day [34],
can explore new testing models. By promoting the norm-
alisation of testing and reducing stigma, they can also cir-
cumvent some policy- and physician-related testing barri-
ers whilst expanding testing uptake [34].
Late presentation: epidemiology and
risk factors
The most recent late presentation figures for Switzerland
come from 1366 patients enrolled in the Swiss HIV Cohort
Study (SHCS) between 2009 and 2012. In this study by
Hachfeld et al., late presentation occurred in 49.8% of
patients presenting for HIV care with variation between
SHCS centres, from 44.4% in Zurich to 58.6% in Basel
[10]. Late presentation was more frequent among women
and individuals from sub-Saharan Africa and less frequent
among highly-educated individuals and MSM. The main
patient-related reasons for late testing were: not feeling
at risk (72%), not feeling ill (65%) and not knowing the
symptoms of HIV (51%). In a single-centre study of 281
patients presenting for HIV care between 2009 and 2011
in Zurich, the late presentation rate was 45% [35]. Risk
factors for late presentation in this study included older age
(odds ratio 3.16 for age ≥50 years vs <30 years), Asian
versus Caucasian ethnicity and being a heterosexual man in
a stable partnership [35].
The largest European analyses come from the Collabor-
ation of Observational HIV Epidemiological Research
Europe Study (COHERE), which includes Swiss data.
Among 84 524 HIV-positive individuals from 23 countries
in Europe presenting for HIV care between 2000 and 2011,
late presentation occurred in 53.8% of patients but de-
creased over the study period from 57.3% in 2000 to 51.7%
in 2010/11 [6]. In this study, late presentation was highest
in heterosexual men (66.1%), individuals treated in south-
ern European countries (57.0%) and individuals from
Africa (65.1%). Factors associated with late presentation
included older age and being of non-European origin [6].
Two other national cohorts reported late presentation asso-
ciations similar to those reported in Switzerland [10, 35].
In the national observational HIV cohort of the Netherlands
(ATHENA), late presentation was examined in 20 965
HIV-infected patients under care at 27 HIV treatment
Table 1: Diseases in which the prevalence of undiagnosed human
immunodeficiency virus (HIV) infection is probably greater than 0.5%:
HIV testing should be recommended. (This is Table 2b of the FOPH
2015 HIV testing recommendations [27].)
Oral hairy leucoplakia Dermatitis / seborrhoeic rash*
Sexually transmitted infections* Invasive pneumococcal disease
Hepatitis B or C (acute or
chronic)*
Candidaemia
Unexplained lymphadenopathy Visceral leishmaniasis
Unexplained leukocytopenia/
thrombocytopenia persisting for
>4 weeks*
Peripheral neuropathy of
unknown origin
Severe or atypical psoriasis Guillain-Barré syndrome
Lymphoma* Mononeuritis
Lung carcinoma Sub-cortical dementia
Anal carcinoma/dysplasia* Multiple sclerosis-like disease
Cervical dysplasia* Unexplained weight loss
Herpes zoster in an individual
<50 years old*
Unexplained oral candidiasis
Unexplained chronic renal
impairment
Unexplained chronic diarrhoea
* The eight indicator diseases from HIDES I
Table 2: Conditions in which not identifying the presence of human
immunodeficiency virus (HIV) infection may have significant adverse
implications for the individual’s clinical management. (This is Table 2c
of the FOPH 2015 HIV testing recommendations together with
indicator conditions listed in the Guidance for Implementing HIV
Testing in Adults in Health Care Settings published by HIV in Europe,
http://newsite.hiveurope.eu/Portals/0/Guidance.pdf.)
Conditions requiring aggressive immunosuppressive therapy:
Cancer
Transplantation
Autoimmune disease treated with immunosuppressive therapy
Primary space occupying lesion of the brain
Idiopathic/thombotic thombocytopenic purpura
Other conditions:
Tuberculosis
Recurrent pneumonia
Pregnancy
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centres between 1996 and 2014 [36]. Although the rate of
late presentation decreased over time from 62% (1996) to
42% (2013), it did not decline significantly among het-
erosexual men and women. In Sweden, Brannstrom et al.
reported late presentation in 58% of 575 newly HIV-dia-
gnosed patients and late presentation was higher in hetero-
sexuals (67%) than in PWID (43%) or MSM (40%). Late
presentation risk factors included being older than 30 years,
originating from sub-Saharan Africa, Eastern Europe, Asia
and the Pacific region, and acquiring HIV in sub-Saharan
Africa [37].
In summary, the late presentation rates in Switzerland and
the rest of Europe vary with region and risk population,
from around 40 to 67%, and risk factors are similar, in-
volving older individuals, heterosexual men and women,
and those of non-European origin.
A foot note on late presentation epidemiology
Although individuals from regions of high HIV prevalence
are not the focus of this review, this group can be highly
vulnerable and often without access to health care, partic-
ularly when arriving in a new country and without doc-
umentation [38, 39]. Whilst many regions worldwide, in-
cluding sub-Saharan Africa, have experienced a reduction
in the number of new HIV infections since 2000 [1], four
regions report a rise in HIV acquisition between 2000 and
2014: North Africa, the Middle East, Central Asia and
Eastern Europe [1]. In the latter part of this period, there
has been large-scale human displacement with people trav-
elling from, or via, these regions to reach Europe [40]. In-
creasing data suggest that migrants from regions of high
HIV prevalence do not necessarily arrive in Europe with
HIV but can acquire the infection through assortative sexu-
al mixing some months or years after arrival [41]. A de-
scription of late presentation epidemiology in Europe
would therefore be incomplete without considering the
combined effect that these three processes – increasing new
HIV infections, human migration and post-migration HIV
acquisition – may have on HIV epidemiology in Switzer-
land and the rest of Europe in the future.
Missed opportunities for HIV testing
Case study 2
A 38-year-old woman is followed intermittently by her GP
for hypertension. Two years after joining the practice, a
routine blood test shows a mild normochromic normocyt-
ic anaemia with a slightly raised erythrocyte sedimenta-
tion rate. Two years later, she is admitted to hospital with
a basal pneumonia complicated by a pleural effusion re-
quiring drainage. CT reveals an ovarian cyst and she is
referred to the gynaecology department. She is found to
have high-grade superficial intraepithelial lesions of the
cervix and cervical intraepithelial neoplasia, for which she
receives treatment and outpatient follow-up over 6 months.
At this point, the aetiology of the anaemia remaining un-
clear, she is referred for a colonoscopy (normal) and upper
gastrointestinal endoscopy, which shows florid oesopha-
geal candidiasis. The gastroenterologist performs an HIV
test which is positive. CD4 count is 30 (3%) and HIV RNA
viral load is 51 000 copies/ml at diagnosis.
Case study 3
A 67-year-old man lives in the Middle East and Switzer-
land, where he has been followed up for 3 years for peri-
pheral vascular disease complicated by intermittent lower
limb soft tissue infection. He has insulin-requiring type 2
diabetes, chronic renal insufficiency secondary to diabetes
and hypertension, and is on thyroid replacement therapy.
He now presents with lower limb cellulitis and confusion.
Blood cultures grow Staphylococcus aureus. The patient
develops signs of cauda equina syndrome. Spinal MRI re-
veals multifocal discitis and a compressive lumbar epidur-
al abscess that requires surgical drainage. While conduct-
ing the preoperative work-up, the attending doctor suffers a
needle-stick injury. An HIV test is performed with the pa-
tient’s consent, in accordance with hospital protocol. The
test is positive. CD4 count is 330 (18%) and HIV RNA vir-
al load is 370 000 copies/ml at diagnosis.
Comment on the case studies
The three case studies describe missed opportunities for
earlier HIV diagnosis in patients of European origin who
had risk factors for late presentation according to the cohort
studies presented here. In the study by Hachfeld et al., 71%
of the 1366 participants were symptomatic during the year
preceding their HIV diagnosis and the majority had presen-
ted to a healthcare provider. A study of 1008 adults living
in France, newly diagnosed with HIV infection between
2009 and 2010, reported that 99% had presented to a health
care setting and 89% had seen a GP at least once a year
during the three years prior to HIV diagnosis [18]. Of 364
patients who sought medical care for possible HIV-related
conditions, 82% had a missed opportunity for testing [18].
In the Swedish study of Brannstrom et al., 27% of all pa-
tients had presented with AIDS and/or HIV-associated con-
ditions without being offered testing. In addition, a recent
case-control study performed in six general practices in
Amsterdam reported that at least one indicator condition
was present in 59% of the cases but in only 7% of controls
during the 5 years prior to HIV testing, leading the authors
to conclude that HIV indicator conditions do not yet trigger
early HIV testing in primary care [42].
We can apply the late presentation risk factor data and the
HIV testing indications to the three case studies to identify
missed opportunities for earlier HIV diagnosis: The patient
in case study 1 underwent HIV testing at an anonymous
testing facility to be diagnosed with HIV, despite having
been followed for 2 years by several doctors in differ-
ent hospitals for three symptoms of those listed in table
1: chronic diarrhoea, unexplained weight loss and lymph-
adenopathy. This case highlights the importance of keeping
up to date with new trends in HIV epidemiology and sub-
sequent testing recommendations. Regarding risk factors,
the patient was assumed to be heterosexual because he was
married with children and was probably not tested because
he was not seen to belong to a classical risk group. The case
demonstrates that, without taking a sexual history, it is dif-
ficult to fully assess HIV risk factors. The patient openly
described his sexual contacts once asked directly but re-
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marked that no one had previously asked him. However,
not all patients disclose a full sexual history and this is
where phrasing the question on HIV testing can be critical.
The patient in case study 2 was not offered testing despite
presenting for care repeatedly over a period of 4 years
with unexplained anaemia, basal pneumonia and cervical
intraepithelial neoplasia. Cervical dysplasia is an indication
for HIV testing, following HIDES I [26, 27]; cervical car-
cinoma has been listed as an AIDS-defining condition
since 1993 [43]. In spite of this, we recently reported HIV
testing rates of 11% among women with invasive cervical
carcinoma treated at Lausanne University Hospital
between 2000 and 2012 [44].
The patient in case study 3 was HIV tested because of a
needle-stick injury, having been followed-up over 3 years
for chronic conditions. Vascular and renal disease consti-
tute SNA events and chronic renal impairment is now an
indication for testing [27]. The association between these
conditions and the patient’s long-standing diabetes and hy-
pertension illustrates the age-old medical dilemma of Oc-
cam’s razor (lex parsimoniae) – promoting a unifying dia-
gnosis based on the rules of probability – versus Hickam’s
dictum – reminding us that patients can have many diseases
concomitantly. The approach of looking for the fewest pos-
sible causes to account for all the symptoms is rational and
appropriate, provided HIV is on the list. In this patient’s
case, vascular and renal disease being due to diabetes and
hypertension can suffice as an explanation once HIV has
been excluded.
How to address late presentation: the
three Ps
The three Ps that contribute to HIV testing barriers and,
therefore, to late presentation – policy, provider and patient
– are the same as those that will address this problem.
On the policy front, this would include means to facilitate
testing by increasing the availability of rapid point-of-care
testing and by targeting the groups at risk of late presenta-
tion as described above. Written consent prior to testing is
not required in Switzerland and this circumvents an import-
ant logistical barrier [32, 33]. Among health care providers,
improved risk assessment, including a detailed sexual his-
tory in patients with medical problems which remain un-
resolved over months or years, recognition of HIV-related
conditions and understanding of the inextricable link
between missed opportunities, late presentation and subse-
quent patient outcome, will help to reduce late presenta-
tion. In addition to missing the opportunity to test when
faced with a testing indication, missed opportunities can
arise among patients visiting more than one physician,
where each doctor imagines one of the others will organise
testing (de Rossi et al., unpublished data). Finally, among
patients, awareness of symptoms related to acute [45] or
advanced HIV infection, and of the benefits of early dia-
gnosis and linkage to care, will improve patient-induced
testing rates.
The following practical points relate to the patient-provider
relationship and may facilitate HIV testing:
‒ Phrasing the question is important
“Have you had unprotected sex since your last HIV
test?” or “When was your last HIV test?” are two ways
of de-dramatising HIV testing, because the implication
is that testing should be a regular part of a health check
in individuals who are or who have been sexually act-
ive. In contrast, asking the question “Do you consider
yourself at risk for HIV infection?” will induce diffi-
culties in manoeuvring the discussion into conducting a
test if the patient’s reply is no.
‒ Thinking wide – and beyond MSM, PWID and indi-
viduals from regions of high HIV prevalence
Any patient with indications for HIV testing should be
tested as soon as these indications become apparent.
Any patient from a population at risk of late presenta-
tion should also be considered for testing: sexually-act-
ive heterosexual men and women, older individuals and
individuals of non-European origin. SNA events and
unexplained and unresolved medical problems are also
indications for testing.
‒ Never assuming
Patients not considered to be part of a high-risk group
can engage in high-risk behaviour. The patient from
case 1 was married with children but had male sexual
partners. No doctor had asked him about his sexual his-
tory. And never assume with patients who have more
than one doctor that one of the other doctors will offer
testing.
Conclusion
In conclusion, one half of HIV-infected individuals who
present for care are late presenters and this has conse-
quences for both individual and public health. The main
risk factors for late presentation in Switzerland are being
female, heterosexual, older and of non-European origin.
Missed opportunities for early HIV testing are frequent
and relate to policy structure, healthcare providers and pa-
tients. Among healthcare providers, knowledge of the na-
tional HIV testing recommendations and awareness of cur-
rent HIV epidemiology trends should serve to encourage
testing in patients before they present late or with SNA
events. Three principles – phrasing the question, thinking
wide, never assuming – should assist in broaching the sub-
ject of HIV testing and performing a test. Above all, having
an open discussion with patients is paramount.
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